As the COVID-19 crisis continues to unfold, there is an immediate need for rapid diagnostic testing to identify and track people infected by or exposed to coronavirus.
While the urgency of the situation has presented a challenge, it has also spurred collaboration and innovation between medical device and diagnostic sponsors, biopharmaceutical companies, diagnostic labs, and nonprofit organisations on an unprecedented scale.
Regulatory authorities are doing their part to accelerate the approval of diagnostic tests through expedited pathways such as the FDA’s Emergency Use Authorization (EUA). This guidance relaxes parameters for approval such as the minimum number of patient samples used for validation. It also allows manufacturers to develop and distribute COVID-19 diagnostic tests after validating and posting their performance characteristics and notifying the FDA, as long as the manufacturer submits an EUA within 15 days. As of April 8, 2020, there are 30 COVID-19 diagnostic tests that have been cleared by the FDA through this pathway.
In this blog, we discuss the different types of diagnostics that have been authorized through this expedited pathway, their advantages and disadvantages, and how a strategic partnership can help diagnostic developers navigate regulatory considerations during this unprecedented time.
Innovating rapid diagnostics
Historically, the gold standard method for infectious disease diagnostics used by testing labs has been reverse transcription of the virus’ RNA followed by PCR amplification (RT-PCR). While RT-PCR is both sensitive and specific, it can take several hours to process and run patient samples.
To improve speed and accessibility, a number of rapid tests can be administered in a point-of-care setting. The first wave of these tests rely on the same underlying RT-PCR method, with various modifications to shorten the run time and reduce dependence on specialized lab equipment. For instance, the Cepheid Xpert® Xpress SARS-CoV-2 test, Mesa Biotech’s Accula SARS-CoV-2 test, as well as the Biomerieux BioFire COVID-19 test can all be run in less than an hour on smaller machines that are available at many hospitals.
Another variation on traditional RT-PCR-based diagnostics are tests that use isothermal amplification. These tests bypass the need for temperature cycling altogether, and in a point-of-care setting, can provide the fastest test result. For example, Abbott’s ID NOW COVID-19 test detects a positive result in 5 minutes and detects a negative result in 9 minutes.
Detecting antibodies with immunoassays
Immunoassays for SARS-CoV-2 have lagged behind other testing modalities due to the lack of disease-specific antibody targets. However, the widespread adoption of antibody testing is essential to determine whether an individual is immune to COVID-19 and can safely resume normal activities.
As of the time of writing, the Cellex qSARS-CoV-2 IgG/IgM Rapid Test is the only test that has been cleared under EUA. This is a lateral flow immunoassay, often referred to as a dipstick test, which can be used to detect antibodies indicating immunity to the virus in serum, plasma or whole blood in a laboratory setting. Seven additional COVID-19 immunoassays have been approved for diagnostic use outside the U.S., though none have received a EUA yet.
COVID-19 clinical operations
Keeping your clinical trial on track in an evolving environment.
Sequencing the whole virome
Next-generation sequencing of the SARS-CoV-2 virome is another approach that – while slower than PCR-based tests – can provide valuable insights into the epidemiology of the COVID-19 pandemic. A recent study of samples from the outbreak in Italy used Thermo Fisher Scientific’s AmpliSeq SARS-CoV-2 Research Panel for Ion Torrent sequencers to show that the novel coronavirus is slow-mutating. These findings suggest that a vaccine could be effective at preventing infection for many years.
Emerging technologies
The first few waves of expedited approvals have been based on established technologies that are backed by decades of data. However, a number of tests based on newer technologies are also in the pipeline, including the first CRISPR-based diagnostic tests. Both Sherlock Biosciences and Mammoth Biosciences are developing diagnostic tests using a variant of the CRISPR system that emits a visible signal in the presence of a SARS-CoV-2 specific RNA sequence. Moreover, these tests can be commercialized for the point-of-care setting with simple temperature control equipment, and with further research, for at-home use in the future.
The path forward for diagnostics manufacturers
The COVID-19 pandemic continues to drive collaboration and innovation in the diagnostics industry. ICON has quickly mobilised its laboratory and medical device and diagnostics experts to assist both government and commercial clients in addressing the COVID-19 global threat by providing diagnostic testing, clinical monitoring, program oversight, and strategy and safety oversight on numerous coronavirus trials. Contact us to speak with our experts today.
Infectious diseases and vaccines insights
ICON's Infectious Diseases and Vaccines teams contribute regularly to media and industry conversations in addition to the production of thought leadership content in the form of whitepapers and blogs.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel